Zacks Research Analysts Increase Earnings Estimates for BAX

Key Points

• Zacks Research raised Baxter International’s Q2 2027 EPS estimate to $0.51 from $0.50, while maintaining a “Hold” rating. Analysts’ consensus full-year EPS estimate is $2.04.
• Baxter’s latest quarterly results exceeded expectations, with EPS of $0.56 versus the $0.37 consensus and revenue of $2.96 billion, up 5.3% year over year.
• Analyst sentiment remains cautious: BAX has an overall “Hold” rating and a consensus price target of $22.45, despite several brokerages recently raising their targets.

Baxter International Inc. (NYSE:BAX - Free Report) - Equities researchers at Zacks Research raised their Q2 2027 EPS estimates for Baxter International in a research note issued to investors on Monday, September 28th. Zacks Research analyst Team now expects that the medical instruments supplier will earn $0.51 per share for the quarter, up from their previous estimate of $0.50. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Baxter International's current full-year earnings is $2.04 per share.

Baxter International (NYSE:BAX - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.19. The company had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $2.80 billion. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm earned $0.59 EPS. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS.

A number of other brokerages also recently issued reports on BAX. The Goldman Sachs Group boosted their price target on Baxter International from $19.00 to $21.00 and gave the company a "neutral" rating in a report on Wednesday, July 15th. Citigroup upgraded shares of Baxter International from a "sell" rating to a "neutral" rating and boosted their target price for the company from $17.00 to $28.00 in a research note on Friday, July 31st. Weiss Ratings upgraded shares of Baxter International from a "sell (d-)" rating to a "sell (d)" rating in a research report on Friday, July 31st. UBS Group upped their price objective on shares of Baxter International from $19.00 to $25.00 and gave the stock a "hold" rating in a research report on Tuesday, July 28th. Finally, Wells Fargo & Company raised their target price on Baxter International from $19.00 to $23.00 and gave the company an "equal weight" rating in a research report on Friday, July 31st. Two investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $22.45.

Baxter International Stock Up 0.6%

Shares of BAX opened at $23.51 on Tuesday. The company has a market capitalization of $12.15 billion, a price-to-earnings ratio of -11.36, a PEG ratio of 3.53 and a beta of 0.60. Baxter International has a 52 week low of $15.73 and a 52 week high of $30.00. The stock's 50-day moving average price is $25.19 and its 200-day moving average price is $21.16. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 1.39.

Hedge Funds Weigh In On Baxter International

A number of large investors have recently added to or reduced their stakes in BAX. Jones Financial Companies Lllp acquired a new stake in shares of Baxter International in the second quarter valued at about $26,000. CYBER HORNET ETFs LLC raised its position in shares of Baxter International by 52.4% during the 2nd quarter. CYBER HORNET ETFs LLC now owns 2,153 shares of the medical instruments supplier's stock worth $46,000 after purchasing an additional 740 shares during the last quarter. Community Bank N.A. acquired a new position in shares of Baxter International during the 2nd quarter worth about $46,000. Versant Capital Management Inc lifted its stake in Baxter International by 552.2% in the 2nd quarter. Versant Capital Management Inc now owns 2,413 shares of the medical instruments supplier's stock valued at $51,000 after buying an additional 2,043 shares in the last quarter. Finally, EFG International AG purchased a new position in Baxter International in the 2nd quarter valued at about $67,000. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Baxter International Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Friday, August 28th will be issued a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend is Friday, August 28th. Baxter International's payout ratio is presently -1.93%.

About Baxter International

Baxter International Inc is a global healthcare company that develops and supplies medical products and technologies used in hospitals, outpatient facilities, physician offices and other care settings. Its offerings include intravenous therapy products and infusion systems, injectable medications and drug-compounding technologies, surgical products, patient-monitoring systems, respiratory-care equipment, and products used in hospital beds and connected-care environments.

The company serves healthcare providers and patients in numerous countries, with operations and customers across North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.